Current Management and New Developments in the Treatment of ALL.
Cancer Treat Res
; 181: 75-96, 2021.
Article
in En
| MEDLINE
| ID: mdl-34626356
With the recent advent of newer targeted therapies, including blinatumomab, inotuzumab ozogamicin, tyrosine kinase inhibitors (TKIs), and CAR T cells, treatment approaches to newly diagnosed as well as relapsed/refractory acute lymphoblastic leukemia (ALL) have changed. This chapter summarizes the newest treatment approaches in newly diagnosed T-cell and B-cell ALL, as well as the use of novel therapies for relapsed and refractory ALL.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Limits:
Humans
Language:
En
Journal:
Cancer Treat Res
Year:
2021
Document type:
Article